Annexon (ANNX) Other Accumulated Expenses (2019 - 2026)
Annexon's (ANNX) quarterly Other Accumulated Expenses came in at $11.0 million in Q1 2026, up 4508.37% year-on-year from $239000.0 in Q1 2025, and down 32.37% quarter-over-quarter from $16.3 million in Q4 2025.
Annexon (ANNX) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Annexon's Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $11.0 million for Q1 2026.
- On a quarterly basis, Other Accumulated Expenses rose 4508.37% year-over-year to $11.0 million in Q1 2026; TTM through Mar 2026 was $11.0 million, a 4508.37% increase from a year earlier, with the FY2025 full-year figure at $16.3 million, up 11449.65% from the prior year.
- Other Accumulated Expenses eased to $11.0 million in Q1 2026 per ANNX's latest filing, from $16.3 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $16.3 million in Q4 2025 and bottomed at $79000.0 in Q3 2023.
- The 5-year median for Other Accumulated Expenses is $164000.0 (2022), against an average of $3.3 million.
- Across the five-year window, Other Accumulated Expenses sank 94.82% in 2022 and jumped 11449.65% in 2025, its largest moves.
- Year by year, Other Accumulated Expenses stood at $180000.0 in 2022, then retreated by 21.67% to $141000.0 in 2023, then changed by 0.0% to $141000.0 in 2024, then soared by 11449.65% to $16.3 million in 2025, then sank by 32.37% to $11.0 million in 2026.
- Per Business Quant, the three latest ANNX Other Accumulated Expenses figures stand at $11.0 million (Q1 2026), $16.3 million (Q4 2025), and $15.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn |
| 10 | Annexon | 1.03 Bn | 1.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.01 Mn |
| Dec 31, 2025 | 16.29 Mn |
| Sep 30, 2025 | 15.76 Mn |
| Jun 30, 2025 | 132,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Sep 30, 2024 | 206,000.00 |
| Jun 30, 2024 | 113,000.00 |
| Mar 31, 2024 | 4.53 Mn |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | 79,000.00 |
| Jun 30, 2023 | 161,000.00 |
| Mar 31, 2023 | 7.51 Mn |
| Dec 31, 2022 | 180,000.00 |
| Sep 30, 2022 | 164,000.00 |
| Jun 30, 2022 | 120,000.00 |
| Mar 31, 2022 | 84,000.00 |
| Dec 31, 2021 | 2.40 Mn |
| Sep 30, 2021 | 3.17 Mn |
| Jun 30, 2021 | 298,000.00 |